▌技術簡介(現況)
雙特異性抗體已成為次世代抗體藥物開發主流，然而已上市的BiTE雙特異性抗體有半衰期較差的缺陷，生技中心所開發之長效型抗癌雙特異性抗體係利用抗體的一端標靶癌細胞，並利用抗體的另一端誘導T細胞至癌細胞周圍，以活化T細胞並進行癌細胞毒殺，在胰臟癌動物試驗中已發現在降低給藥頻率時，其療效優於半衰期差的Fragment BsAb，且療效亦較單株抗體藥物為佳。

▌技術規格
人源化非對稱性IgG雙特異性抗體(asymmetric-BsAb)開發平台/ anti-mesothelin/anti-CD3雙特異性抗體。

▌技術特色
針對癌細胞進行新世代標靶治療，利用雙特異性抗體誘導活化T細胞並針對癌細胞進行毒殺，其療效較傳統單株抗體為佳。

▌應用範圍
Mesothelin高表現的Mesothelioma、胰臟癌、及卵巢癌之治療，或其他。

▌接受技術者具備基礎建議（設備）
一般分子生物學實驗設施、抗體表現與純化系統。

▌接受技術者具備基礎建議（專業）
抗體臨床前開發技能。

▌技術分類
抗體藥物開發。

▌專利狀態
已申請專利國家: 美國

聯絡人 鄭惠娟
TEL  02-26956933 #2431
FAX  02-2694-5648
E-mail  hjjeng@dcb.org.tw

 

 

Technology/ Title

Asymmetric Bispecific Antibody Technology for Cancer Therapy

Technology Type

□Biotechnology

□Device/Diagnostics

■Pharmaceutical

□Others:_____________-

Contact Person

Name: Tony Chung

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5235

Mobile:

Email: tony.chung@dcb.org.tw

 

 

Technology Description

 

Summary of Invention:

Bispecific antibody (BsAb) is the trend of next generation antibody drug development. There are two BsAbs approved to be used in the clinics. Among these two, the bispecific T cell engager (BiTE) uses protein engineering to bypass the mispairing issue between light chains and heavy chains. However, the short half-life is the main drawback of this technology. DCB has developed a long half-life BsAb. It showed great efficacy in the breast cancer xenograft animal model.

.

Advantages when compared to the existing technologies:

  1. Correct light chain and heavy chain pairing.
  2. Long half-life.
  3. Target-dependent T cell activation.
  4. Great anti-cancer efficacy in breast cancer animal model.

Intellectual Property

TW, US, PCT patents applied

Business Opportunity

Cancer Therapy: Breast Cancer.